CoChat

The diagnosis and management of central hypothyroidism in 2018

Open access
Persani, Luca, Cangiano, Biagio, Bonomi, Marco · 2019 · Endocrine Connections

The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index; 5 of the 70 sources its claims cite were checked for support.

Abstract

Central hypothyrodism (CeH) is a hypothyroid state caused by an insufficient stimulation by thyrotropin (TSH) of an otherwise normal thyroid gland. Several advancements, including the recent publication of expert guidelines for CeH diagnosis and management, have been made in recent years thus increasing the clinical awareness on this condition. Here, we reviewed the recent advancements and give expert opinions on critical issues. Indeed, CeH can be the consequence of various disorders affecting either the pituitary gland or the hypothalamus. Recent data enlarged the list of candidate genes for heritable CeH and a genetic origin may be the underlying cause for CeH discovered in pediatric or even adult patients without apparent pituitary lesions. This raises the doubt that the frequency of CeH may be underestimated. CeH is most frequently diagnosed as a consequence of the biochemical assessments in patients with hypothalamic/pituitary lesions. In contrast with primary hypothyroidism, low FT4 with low/normal TSH levels are the biochemical hallmark of CeH, and adequate thyroid hormone replacement leads to the suppression of residual TSH secretion. Thus, CeH often represents a clinical challenge because physicians cannot rely on the use of the ‘reflex TSH strategy’ for screening or therapy monitoring. Nevertheless, in contrast with general assumption, the finding of normal TSH levels may indicate thyroxine under-replacement in CeH patients. The clinical management of CeH is further complicated by the combination with multiple pituitary deficiencies, as the introduction of sex steroids or GH replacements may uncover latent forms of CeH or increase the thyroxine requirements.

Overview

CoChat Summary

TL;DR

Central hypothyroidism (CeH) is caused by insufficient TSH stimulation of an otherwise normal thyroid and is biochemically marked by low free T4 with low/normal TSH, making the reflex TSH strategy unreliable for screening and monitoring. This narrative review summarizes recent genetic, diagnostic, and therapeutic advances, including the 2018 ETA guidelines, and emphasizes L-T4 replacement targeted to FT4 rather than TSH.

Key findings

  • CeH incidence was estimated at 1:16,000 to about 1:100,000 in different adult or neonatal hypothyroid populations; prevalence is suspected to be underestimated because acquired forms and genetic cases may be missed. The Dutch diagnostic strategy using total T4, thyroxine-binding globulin, and TSH was more sensitive than strategies based on low total T4 plus normal/low TSH used in Japan and the USA.
  • The biochemical hallmark is low FT4 with low or normal TSH; diagnosis cannot be achieved by single TSH measurement, and FT4 has the highest diagnostic sensitivity and specificity. Conditions such as nonthyroidal illness, TSH-inhibiting drugs, thyrotoxicosis-related states, pregnancy-related hypothyroxinemia, and assay interference must be excluded. In CeH patients with normal TSH at diagnosis, lack of TSH suppression during L-T4 may indicate under-replacement.
  • Genetic causes have expanded; IGSF1 followed by PROP1 are the genes most frequently accounting for inheritable CeH. Candidate genes include isolated CeH genes (TSHβ, TRHR, TBL1X, IRS4) and multiple pituitary hormone deficiency genes; acquired CeH is mainly due to pituitary macroadenomas, craniopharyngiomas, cranial surgery or irradiation, head trauma, vascular accidents, autoimmune disease, infiltrative lesions, and infections.
  • First-line treatment is levothyroxine (L-T4), started after excluding or treating cortisol deficit. Adequacy is evaluated after 6–8 weeks by targeting FT4 above the median of the reference range, then annually; starting doses are 1.0–1.2 μg/kg/day in patients older than 60 years or with cardiovascular comorbidities. Severe congenital CeH should be treated within 2 weeks of birth at 10–12 μg/kg/day, milder congenital forms at 5–10 μg/kg/day, childhood at 3.0–5.0 μg/kg/day, and adolescence at 2.0–2.4 μg/kg/day; pregnancy requires a 20–50% increase and FT4 in the upper quartile. Combined L-T4/L-T3 is not generally supported, though it may be considered in patients with the DIO2 Thr92Ala polymorphism or persistent symptoms despite adequate L-T4.

Methods

  • Narrative review and expert opinion synthesizing recent advancements and the 2018 European Thyroid Association guidelines on CeH diagnosis and management.
  • No primary data collection, systematic search strategy, inclusion criteria, or meta-analysis is described; the paper presents tables of candidate genes, acquired causes, differential diagnoses, and conditions requiring therapy adjustment.

Limitations

  • The paper states that CeH diagnosis and management remain challenging due to lack of accurate clinical and biochemical parameters; recognition of mild or hidden CeH is hampered by the lack of a sufficiently sensitive parameter, and interpretation of diagnostic tests is controversial and resource-dependent.
  • The paper states that combined L-T4/L-T3 therapy may carry a higher risk of thyrotoxicosis in CeH because there is no highly reliable parameter to check overtreatment, and studies failing to show benefit may lack power because the DIO2 polymorphism is relatively infrequent.
  • Evident from the text: this is a narrative review rather than a systematic evidence synthesis, and some cited evidence includes a prospective study performed on a small number of patients, so selection and reporting bias cannot be excluded.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1530/ec-18-0515

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flowchart for the diagnosis of CeH. CeH, central hypothyroidism; COS, controlled ovarian stimulation; ES, empty sella; IO, iron overload or hemochromatosis; MPHD, multiple pituitary hormone defect; MRI, magnetic resonance imaging; PID, pituitary infiltrative disease; PSI, pituitary stalk interruption; rhGH, recombinant human growth hormone; TBI, traumatic brain injury; VA, vascular accident.
Figure 1 Flowchart for the diagnosis of CeH. CeH, central hypothyroidism; COS, controlled ovarian stimulation; ES, empty sella; IO, iron overload or hemochromatosis; MPHD, multiple pituitary hormone defect; MRI, magnetic resonance imaging; PID, pituitary infiltrative disease; PSI, pituitary stalk interruption; rhGH, recombinant human growth hormone; TBI, traumatic brain injury; VA, vascular accident.CC BY-NC · PubMed Central

Verification

Claims the paper makes

5 Valid · 13 Not valid · 37 Not checked · 33 Own results and interpretations

52 more claims

Create a free account to see all 88 claims and to verify the 64 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 25

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 72 references

Research works printed but not linked: 70

  1. 2008, Mechanisms related to the pathophysiology and management of central hypothyroidism, Nature Clinical Practice: Endocrinology and Metabolism, 4, 683
  2. Klose M Marina D Hartoft-Nielsen ML Klefter O Gavan V Hilsted L Rasmussen AK Feldt-Rasmussen U. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2013 98 3802– 3810. (10.1210/jc.2013-1610) 23796569 · DOI · Paper page
  3. LaFranchiSH, screening strategies for congenital hypothyroidism an update of Disease https org, Journal Inherited Metabolic, 201033, 10.1007/s10545-010-9062-1 · DOI · Paper page
  4. Persani L Tonacchera M Beck-Peccoz P Vitti P Mammoli C Chiovato L Elisei R Faglia G Ludgate M Vassart G Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin. Journal of Endocrinological Investigation 1993 16 511– 519. (10.1007/BF03348894) 8227980 · DOI · Paper page
  5. Koch CA Sarlis NJ. The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. Journal of Endocrinological Investigation 2001 24 659– 675. (10.1007/BF03343911) 11716153 · DOI · Paper page
  6. Pfäffle R Klammt J Pituitary transcription factors in the aetiology of combined pituitary hormone deficiency. Best Practice and Research. Clinical Endocrinology and Metabolism 2011 25 43– 60. (10.1016/j.beem.2010.10.014) 21396574 · DOI · Paper page
  7. Jonklaas J Bianco AC Bauer AJ Burman KD Cappola AR Celi FS Cooper DS Kim BW Peeters RP Rosenthal MS, Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014 24 1670– 1751. (10.1089/thy.2014.0028) 25266247 PMC4267409 · DOI · Paper page
  8. 2012, Mass screening of newborns for congenital hypothyroidism of central origin by free thyroxine measurement of blood samples on filter paper, European Journal of Endocrinology, 166, 829, 10.1530/eje-11-0653 · DOI · Paper page
  9. Recent advances in central congenital hypothyroidism of https org, Journal Endocrinology, 51
  10. 2012, Clinical review: entral hypothyroidism: pathogenic, diagnostic, and therapeutic challenges, Journal of Clinical Endocrinology and Metabolism, 97, 3068, 10.1210/jc.2012-1616 · DOI · Paper page
  11. Panicker V Saravanan P Vaidya B Evans J Hattersley AT Frayling TM Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1623– 1629. (10.1210/jc.2008-1301) 19190113 · DOI · Paper page
  12. 1999, Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism, Journal of Clinical Endocrinology and Metabolism, 84, 924
  13. Appelhof BC Peeters RP Wiersinga WM Visser TJ Wekking EM Huyser J Schene AH Tijssen JGP Hoogendijk WJG Fliers E. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. Journal of Clinical Endocrinology and Metabolism 2005 90 6296– 6299. (10.1210/jc.2005-0451) 16144953 · DOI · Paper page
  14. Atmaca H Tanriverdi F Gokce C Unluhizarci K Kelestimur F. Do we still need the TRH stimulation test? Thyroid 2007 17 529– 533. (10.1089/thy.2006.0311) 17614773 · DOI · Paper page
  15. Benvenga S Capodicasa G Perelli S. L-thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Frontiers in Endocrinology 2017 8 321 (10.3389/fendo.2017.00321) 29209276 PMC5701926 · DOI · Paper page
  16. 1994, Variable biological activity of thyroid-stimulating hormone, European Journal of Endocrinology, 131, 331, 10.1530/eje.0.1310331 · DOI · Paper page
  17. Alexopoulou O Beguin C De P Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. European Journal of Endocrinology 2004 150 1– 8. (10.1530/eje.0.1500001) 14713273 · DOI · Paper page
  18. 2012, Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality, Archives of Internal Medicine, 172, 811
  19. Persani L Beck-Peccoz P. Central hypothyroidism. In Werner and Ingbar’s the Thyroid: A Fundamental and Clinical Text, 10th ed., Chapter 38, pp 560– 568. Eds Braverman L & Cooper D Philadelphia, PA, USA: Lippincott Williams & Wilkins/Wolters Kluwer Health, 2012.
  20. Ryder M Callahan M Postow MA Wolchok J Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer 2014 21 371– 381. (10.1530/ERC-13-0499) 24610577 PMC4573438 · DOI · Paper page
  21. 2013, The unusual adequate development of a child with severe central hypothyroidsm negative at neonatal thyrotropin screening, Journal of Endocrinological Investigation, 36, 788
  22. Demers LM Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clinical Endocrinology 2003 58 138– 140. (10.1046/j.1365-2265.2003.01681.x) 12580927 · DOI · Paper page
  23. Rose SR Cranial irradiation and central hypothyroidism. Trends in Endocrinology and Metabolism 2001 12 97– 104. (10.1016/S1043-2760(00)00359-3) 11306333 · DOI · Paper page
  24. Joustra SD Heinen CA Schoenmakers N Bonomi M Ballieux BEPB Turgeon M-O Bernard DJ Fliers E Trotsenburg ASP van Losekoot M, IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. Journal of Clinical Endocrinology and Metabolism 2016 101 1627– 1636. (10.1210/jc.2015-3880) 26840047 PMC4880178 · DOI · Paper page
  25. Wiersinga WM Duntas L Fadeyev V Nygaard B Vanderpump MPJ. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. European Thyroid Journal 2012 1 55– 71. (10.1159/000339444) 24782999 PMC3821467 · DOI · Paper page
  26. 1979, Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin, Journal of Clinical Endocrinology and Metabolism, 48, 989, 10.1210/jcem-48-6-989 · DOI · Paper page
  27. 2001, Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene, Journal of Clinical Endocrinology and Metabolism, 86, 1600
  28. Hayashizaki Y Hiraoka Y Endo Y Miyai K Matsubara K Thyroid-stimulating hormone (TSH) deficiency caused by a single base substitution in the CAGYC region of the beta-subunit. EMBO Journal 1989 8 2291– 2296. (10.1002/j.1460-2075.1989.tb08355.x) 2792087 PMC401161 · DOI · Paper page
  29. 1985, Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone, New England Journal of Medicine, 312, 1085, 10.1056/nejm198504253121703 · DOI · Paper page
  30. Jostel A Ryder WDJ Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: definition and evaluation of the TSH Index. Clinical Endocrinology 2009 71 529– 534. (10.1111/j.1365-2265.2009.03534.x) 19226261 · DOI · Paper page
  31. 2018, A novel IGSF1 mutation in a large Irish kindred highlights the need for familial screening in the IGSF1 deficiency syndrome, Clinical Endocrinology, 89, 813, 10.1111/cen.13827 · DOI · Paper page
  32. 2010, Newborn screening results in children with central hypothyroidism, Journal of Pediatrics, 156, 990, 10.1016/j.jpeds.2009.12.011 · DOI · Paper page
  33. 2016, Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients, Endocrine, 54, 15, 10.1007/s12020-016-1047-x · DOI · Paper page
  34. Benaglia L Busnelli A Somigliana E Leonardi M Vannucchi G De S Fugazzola L Ragni G Fedele L. Incidence of elevation of serum thyroid-stimulating hormone during controlled ovarian hyperstimulation for in vitro fertilization. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2014 173 53– 57. (10.1016/j.ejogrb.2013.11.003) 24332278 · DOI · Paper page
  35. Refetoff S Bassett JH Beck-Peccoz P Bernal J Brent G Chatterjee K De Groot LJ Dumitrescu AM Jameson JL Kopp PA, et al Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. European Thyroid Journal 2014 3 7– 9. (10.1159/000358180) 24847459 PMC4005262 · DOI · Paper page
  36. Shimon I Cohen O Lubetsky A Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 2002 12 823– 827. (10.1089/105072502760339406) 12481949 · DOI · Paper page
  37. Doin FC Rosa-Borges M Martins MRA Moisés VA Abucham J. Diagnosis of subclinical central hypothyroidism in patients with hypothalamic–pituitary disease by Doppler echocardiography. European Journal of Endocrinology 2012 166 631– 640. (10.1530/EJE-11-0907) 22267279 · DOI · Paper page
  38. Mechanisms in an update in the genetic aetiologies of combined pituitary hormone deficiency of https org, Endocrinology European Journal Endocrinology, 2016174, 10.1530/eje-15-1095 · DOI · Paper page
  39. 2018, 2018 European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism, European Thyroid Journal, 7, 225, 10.1159/000491388 · DOI · Paper page
  40. 2001, Screening for central hypothyroidism is unjustified, BMJ, 322, 798, 10.1136/bmj.322.7289.798 · DOI · Paper page
  41. Pappa T Johannesen J Scherberg N Torrent M Dumitrescu A Refetoff SA. TSHβ variant with impaired immunoreactivity but intact biological activity and its clinical implications. Thyroid 2015 25 869– 876. (10.1089/thy.2015.0096) 25950606 PMC4533086 · DOI · Paper page
  42. 2010, New cases of isolated congenital central hypothyroidism due to homozygous thyrotropin beta gene mutations: a pitfall to neonatal screening, Thyroid, 20, 639, 10.1089/thy.2009.0462 · DOI · Paper page
  43. Cassio A Cacciari E Cicognani A Damiani G Missiroli G Corbelli E Balsamo A Bal M Gualandi S. Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? Pediatrics 2003 111 1055– 1060. (10.1542/peds.111.5.1055) 12728088 · DOI · Paper page
  44. 2016, Mutations in TBL1X are associated with central hypothyroidism, Journal of Clinical Endocrinology and Metabolism, 101, 4564, 10.1210/jc.2016-2531 · DOI · Paper page
  45. Aleksander PE Brückner-Spieler M Stoehr AM Lankes E Kühnen P Schnabel D Ernert A Stäblein W Craig ME Blankenstein O, Mean high-dose l-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2018 103 1459– 1469. (10.1210/jc.2017-01937) 29325045 · DOI · Paper page
  46. 2017, Central hypothyroidism – a neglected thyroid disorder, Nature Reviews Endocrinology, 13, 588, 10.1038/nrendo.2017.47 · DOI · Paper page
  47. Portes ES Oliveira JH MacCagnan P Abucham J. Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children. Clinical Endocrinology 2000 53 183– 189. (10.1046/j.1365-2265.2000.01071.x) 10931099 · DOI · Paper page
  48. 2007, Interactions between growth hormone and the thyroid gland – with special reference to biochemical diagnosis, Current Medicinal Chemistry, 14, 2783, 10.2174/092986707782360114 · DOI · Paper page
  49. 2017, The multiple genetic causes of central hypothyroidism, Best Practice and Research: Clinical Endocrinology and Metabolism, 31, 255, 10.1016/j.beem.2017.04.003 · DOI · Paper page
  50. 2006, Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls, Journal of Clinical Endocrinology and Metabolism, 91, 3370, 10.1210/jc.2006-0058 · DOI · Paper page
  51. 1995, Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison between in vivo 3,5,3′-triiodothyronine response to TSH and in vitro bioactivity of TSH, Journal of Clinical Endocrinology and Metabolism, 80, 1124
  52. Genetic overlap in Kallmann syndrome combined pituitary hormone deficiency and septo - optic dysplasia of and https org, Journal Clinical Endocrinology Metabolism, 201297, 10.1210/jc.2011-2938 · DOI · Paper page
  53. 1997, A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene, Journal of Clinical Endocrinology and Metabolism, 82, 1561
  54. 1971, Familial isolated thyrotropin deficiency with cretinism, New England Journal of Medicine, 285, 1043, 10.1056/nejm197111042851902 · DOI · Paper page
  55. 2013, The IGSF1 deficiency syndrome: characteristics of male and female patients, Journal of Clinical Endocrinology and Metabolism, 98, 4942, 10.1210/jc.2013-2743 · DOI · Paper page
  56. 1990, Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone beta-subunit gene, American Journal of Human Genetics, 46, 988
  57. Feldt-Rasmussen U Klose M Benvenga S. Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions. Endocrine 2018 62 519– 527. (10.1007/s12020-018-1738-6) 30191443 · DOI · Paper page
  58. Bianco AC Casula S. Thyroid hormone replacement therapy: three ‘simple’ questions, complex answers. European Thyroid Journal 2012 1 88– 98. (10.1159/000339447) 24783002 PMC3821470 · DOI · Paper page
  59. 2012, Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement, Nature Genetics, 44, 1375, 10.1038/ng.2453 · DOI · Paper page
  60. Yamakita N Komaki T Takao T Murai T Hashimoto K Yasuda K. Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion. Journal of Clinical Endocrinology and Metabolism 2001 86 1054– 1060. (10.1210/jcem.86.3.7267) 11238485 · doi:10.1210/jcem.86.3.7267 · Paper page
  61. 2000, Circulating thyrotropin bioactivity in sporadic central hypothyroidism, Journal of Clinical Endocrinology and Metabolism, 85, 3631
  62. 2018, Mutations in IRS4 are associated with central hypothyroidism, Journal of Medical Genetics, 55, 693, 10.1136/jmedgenet-2017-105113 · DOI · Paper page
  63. 2011, What should be done when thyroid function tests do not make sense?, Clinical Endocrinology, 74, 673, 10.1111/j.1365-2265.2011.04023.x · DOI · Paper page
  64. 2012, Central hypothyroidism, Werner and Ingbar’s the Thyroid: A Fundamental and Clinical Text, 560
  65. Slawik M Klawitter B Meiser E Schories M Zwermann O Borm K Peper M Lubrich B Hug MJ Nauck M, Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. Journal of Clinical Endocrinology and Metabolism 2007 92 4115– 4122. (10.1210/jc.2007-0297) 17711927 · DOI · Paper page
  66. Faglia G. The clinical impact of the thyrotropin-releasing hormone test. Thyroid 1998 8 903– 908. (10.1089/thy.1998.8.903) 9827657 · DOI · Paper page
  67. 2011, Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine, Clinical Endocrinology, 74, 744, 10.1111/j.1365-2265.2011.03984.x · DOI · Paper page
  68. 1971, Effect of thyrotropin-releasing factor on serum thyroid-stimulating hormone. An approach to distinguishing hypothalamic from pituitary forms of idiopathic hypopituitary dwarfism, Journal of Clinical Investigation, 50, 2219, 10.1172/jci106717 · DOI · Paper page
  69. Hartoft-Nielsen ML Lange M Rasmussen AK Scherer S Zimmermann-Belsing T Feldt-Rasmussen U. Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Hormone Research 2004 61 53– 57. (10.1159/000075239) 14646390 · DOI · Paper page
  70. 2009, A family with complete resistance to thyrotropin-releasing hormone, New England Journal of Medicine, 360, 731, 10.1056/nejmc0808557 · DOI · Paper page

Cited by

See all 70

Metadata

Authors
Persani, L., Cangiano, B., & Bonomi, M.
Affiliations
University of Milan (IT)
Corresponding author
Persani, Luca
Venue
Endocrine Connections
Published
2019-02
Volume
8
Issue
2
Pages
R44-R54
ISSN
2049-3614 (ISSN-L)
OpenAlex
W2910846975
Cited by
64
References
73
Citations by year
2026: 6 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 10 · 2021: 16 · 2020: 5 · 2019: 2
FWCI
1.27
Type
journal article
Language
en
Open access
Locations
  • Endocrine Connections (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Istituto Auxologico Italiano
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
central hypothyroidism, thyroid-stimulating hormone, pituitary disorders, hypothalamic disorders, candidate genes, thyroid hormone replacement, TSH suppression, growth hormone replacement therapy, pediatric hypothyroidism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The diagnosis and management of central hypothyroidism in 2018. https://app.cochat.ai/papers/10.1530/ec-18-0515
The paper
Persani, L., Cangiano, B., & Bonomi, M. (2019). The diagnosis and management of central hypothyroidism in 2018. Endocrine Connections. https://doi.org/10.1530/ec-18-0515

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.